US FDA accepts GSK's sNDA for Zejula for first-line maintenance treatment for women with platinum-responsive advanced ov

Source :: PharmaBiz. February 25, 2020
Publication Year :: 2020
Abstract: GlaxoSmithKline plc announced that the US Food and Drug Administration (FDA) accepted the company's submission of a supplemental New Drug Application (sNDA) seeking approval of Zejula (niraparib) as a maintenance [...]

Subjects :: United States. Food and Drug Administration
GlaxoSmithKline PLC
Niraparib
Bevacizumab
Chemotherapy
Pembrolizumab
Pharmaceutical industry
Women
Drug approval
Ovarian cancer -- Care and treatment
Time
Cancer treatment
Setting (Literature)
Cancer
Pharmaceuticals and cosmetics industries
Zejula (Medication)

Tools